Chronic kidney disease in cardiorenal syndrome N18
Conditions
Interventions
Group 1: Patients with cardiorenal disease are assessed at the baseline and after 6 and 12 months. The following parameters are collected: anamnesis, physical examination, sonography of the kidney, la
Sponsors
Universitätsmedizin Göttingen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Adult patients capable of consent - Age = 18 years - Outpatients able to consent and cooperate - Written consent to study participation - Patients with a cardio-renal risk profile on stable guideline medication for > 3 months (at least 1 of the following applies): A) Patients for whom SGLT2 inhibitor therapy is planned as part of best clinical practice: Diabetes mellitus II with nephropathy (group 1) CKD and HFrEF (echocardiographically confirmed) (Group 2) CKD without diabetes (Group 3) CKD and HFpEF (Group 7) B) independent of further treatment: Patients with arterial hypertension without HFpEF (group 4) Patients with arterial hypertension with HFpEF (group 5) control group Inclusion Criteria: • Outpatients and inpatients at the Clinic for Nephrology and Rheumatology • Age = 18 years • Written consent to study participation • No evidence of renal or cardiac disease on physical examination
Exclusion criteria
Exclusion criteria: - Patients who have had a kidney transplant (NTX) or require dialysis - Chronic renal insufficiency CKD stage> G4 ( 40 kg / m2, etc.) Circumstances that could interfere with participation in the study (e.g. known non-adherence) Control group Exclusion criteria • Heart failure (HFpEF, HFmrEF, HFrEF) • diabetes mellitus • Refractory hypertension • Albuminuria> 30mg / g creatinine • eGFR 20 mg / l • Circumstances that could interfere with the results of the Doppler sonographic evaluation (e.g. clearly restrictive respiratory diseases, strongly fluctuating blood pressure values, BMI> 40 kg / m2 etc.) • Circumstances that could interfere with participation in the study (e.g. known non-adherence) • Pregnancy or breastfeeding
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Correlation of renal venous congestion and laboratory biomarkers with the renal outcome of the patients. | — |
Primary
| Measure | Time frame |
|---|---|
| Evaluation of renal venous congestion in the different groups of patients at cardiorenal risk and the control group. Evaluation of the development of renal-venous congestion as well as laboratory biomarkers in patients who receive therapy with an SGLT2 inhibitor due to their underlying disease. | — |
Countries
Germany
Contacts
Public ContactManuel Wallbach
Universitätsmedizin Göttingen
Outcome results
None listed